[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Tofacitinib.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Tofacitinib.]
[L01AD04, streptozocin, Streptozocin may increase the immunosuppressive activities of Tofacitinib.]
[L04AA27, fingolimod, Fingolimod may increase the immunosuppressive activities of Tofacitinib.]
[J01EC01, sulfamethoxazole, The metabolism of Tofacitinib can be decreased when combined with Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Tofacitinib.]
[L01BB02, mercaptopurine, Mercaptopurine may increase the immunosuppressive activities of Tofacitinib.]
[L02BA01, tamoxifen, The metabolism of Tofacitinib can be decreased when combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Tofacitinib can be decreased when combined with Teniposide.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Tofacitinib.]
[S03AA02, tetracycline, The metabolism of Tofacitinib can be decreased when combined with Tetracycline.]
[L04AX02, thalidomide, Thalidomide may increase the immunosuppressive activities of Tofacitinib.]
[L01XX41, eribulin, Eribulin may increase the immunosuppressive activities of Tofacitinib.]
[L01AC01, thiotepa, Thiotepa may increase the immunosuppressive activities of Tofacitinib.]
[L01BB03, thioguanine, Tioguanine may increase the immunosuppressive activities of Tofacitinib.]
[N05CA19, thiopental, The metabolism of Tofacitinib can be decreased when combined with Thiopental.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Tofacitinib.]
[S01ED01, timolol, Timolol may increase the bradycardic activities of Tofacitinib.]
[N06AF04, tranylcypromine, The metabolism of Tofacitinib can be decreased when combined with Tranylcypromine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Tofacitinib.]
[L01XF01, tretinoin, Tretinoin may increase the immunosuppressive activities of Tofacitinib.]
[S01BA05, triamcinolone, Triamcinolone may increase the immunosuppressive activities of Tofacitinib.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Tofacitinib.]
[S01AD02, trifluridine, Trifluridine may increase the immunosuppressive activities of Tofacitinib.]
[D07AC02, fluclorolone, Fluclorolone may increase the immunosuppressive activities of Tofacitinib.]
[R03BA07, mometasone, Mometasone may increase the immunosuppressive activities of Tofacitinib.]
[A03AA05, trimebutine, Tofacitinib may increase the bradycardic activities of Trimebutine.]
[N03AC02, trimethadione, Trimethadione may increase the bradycardic activities of Tofacitinib.]
[J01FA08, troleandomycin, The metabolism of Tofacitinib can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Tofacitinib.]
[L04AA26, belimumab, Belimumab may increase the immunosuppressive activities of Tofacitinib.]
[L02BX03, abiraterone, The metabolism of Tofacitinib can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Tofacitinib can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Tofacitinib can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Tofacitinib can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Tofacitinib can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Tofacitinib.]
[L04AA28, belatacept, Belatacept may increase the immunosuppressive activities of Tofacitinib.]
[B01AF01, rivaroxaban, The risk or severity of bleeding can be increased when Rivaroxaban is combined with Tofacitinib.]
[B01AC24, ticagrelor, The metabolism of Tofacitinib can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Tofacitinib can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Tofacitinib can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Tofacitinib can be decreased when combined with Vinblastine.]
[L01CA02, vincristine, Vincristine may increase the immunosuppressive activities of Tofacitinib.]
[L01CA03, vindesine, Vindesine may increase the immunosuppressive activities of Tofacitinib.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tofacitinib.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Warfarin is combined with Tofacitinib.]
[J05AF01, zidovudine, Zidovudine may increase the immunosuppressive activities of Tofacitinib.]
[J05AE02, indinavir, The metabolism of Tofacitinib can be decreased when combined with Indinavir.]
[L01FX05, brentuximab vedotin, The metabolism of Tofacitinib can be decreased when combined with Brentuximab vedotin.]
[L01ED01, crizotinib, The metabolism of Tofacitinib can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Tofacitinib.]
[R03DC01, zafirlukast, The metabolism of Tofacitinib can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Tofacitinib can be decreased when combined with Rabeprazole.]
[N05AE04, ziprasidone, The metabolism of Tofacitinib can be decreased when combined with Ziprasidone.]
[L04AA34, alemtuzumab, Alemtuzumab may increase the immunosuppressive activities of Tofacitinib.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Tofacitinib.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the immunosuppressive activities of Tofacitinib.]
[C07AB03, atenolol, Atenolol may increase the bradycardic activities of Tofacitinib.]
[L03AB11, peginterferon alfa-2a, Peginterferon alfa-2a may increase the immunosuppressive activities of Tofacitinib.]
[L01FA01, rituximab, Rituximab may increase the immunosuppressive activities of Tofacitinib.]
[J02AC03, voriconazole, The metabolism of Tofacitinib can be decreased when combined with Voriconazole.]
[R07AX02, ivacaftor, The metabolism of Tofacitinib can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, Prednylidene may increase the immunosuppressive activities of Tofacitinib.]
[L01BC07, azacitidine, Azacitidine may increase the immunosuppressive activities of Tofacitinib.]
[L04AX01, azathioprine, Azathioprine may increase the immunosuppressive activities of Tofacitinib.]
[L01BC05, gemcitabine, Gemcitabine may increase the immunosuppressive activities of Tofacitinib.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Tofacitinib.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Tofacitinib is combined with Varicella zoster vaccine (live/attenuated).]
[L01FX02, gemtuzumab ozogamicin, Gemtuzumab ozogamicin may increase the immunosuppressive activities of Tofacitinib.]
[L01XG02, carfilzomib, Carfilzomib may increase the immunosuppressive activities of Tofacitinib.]
[V03AX03, cobicistat, The metabolism of Tofacitinib can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Tofacitinib can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Tofacitinib can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Tofacitinib can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, Teriflunomide may increase the immunosuppressive activities of Tofacitinib.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Tofacitinib.]
[L04AA22, abetimus, Abetimus may increase the immunosuppressive activities of Tofacitinib.]
[H02AA01, aldosterone, Aldosterone may increase the immunosuppressive activities of Tofacitinib.]
[L01EX05, regorafenib, The metabolism of Tofacitinib can be decreased when combined with Regorafenib.]
[J05AE04, nelfinavir, The metabolism of Tofacitinib can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, Bendamustine may increase the immunosuppressive activities of Tofacitinib.]
[C08CA13, lercanidipine, Lercanidipine may increase the bradycardic activities of Tofacitinib.]
[N06DA02, donepezil, Donepezil may increase the bradycardic activities of Tofacitinib.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, Antilymphocyte immunoglobulin (horse) may increase the immunosuppressive activities of Tofacitinib.]
[S01AA13, fusidic acid, The metabolism of Tofacitinib can be decreased when combined with Fusidic acid.]
[H01CB05, pasireotide, The metabolism of Tofacitinib can be decreased when combined with Pasireotide.]
[L01EA05, ponatinib, Ponatinib may increase the immunosuppressive activities of Tofacitinib.]
[B01AF02, apixaban, The risk or severity of bleeding can be increased when Apixaban is combined with Tofacitinib.]
[C10AX12, lomitapide, The metabolism of Tofacitinib can be decreased when combined with Lomitapide.]
[C04AX11, bencyclane, Tofacitinib may increase the bradycardic activities of Bencyclane.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the bradycardic activities of Tofacitinib.]
[L04AX06, pomalidomide, Pomalidomide may increase the immunosuppressive activities of Tofacitinib.]
[L04AX07, dimethyl fumarate, Dimethyl fumarate may increase the immunosuppressive activities of Tofacitinib.]
[L04AA18, everolimus, The metabolism of Tofacitinib can be decreased when combined with Everolimus.]
[L01EC02, dabrafenib, The metabolism of Tofacitinib can be decreased when combined with Dabrafenib.]
[C08EA02, bepridil, Bepridil may increase the bradycardic activities of Tofacitinib.]
[L03AA14, lipegfilgrastim, Tofacitinib may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, Ibrutinib may increase the immunosuppressive activities of Tofacitinib.]
[J05AP05, simeprevir, The metabolism of Tofacitinib can be decreased when combined with Simeprevir.]
[C07AB04, acebutolol, Acebutolol may increase the bradycardic activities of Tofacitinib.]
[A16AA07, metreleptin, The metabolism of Tofacitinib can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The therapeutic efficacy of Apremilast can be decreased when used in combination with Tofacitinib.]
[S03BA03, betamethasone, Betamethasone may increase the immunosuppressive activities of Tofacitinib.]
[S01ED02, betaxolol, Betaxolol may increase the bradycardic activities of Tofacitinib.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Tofacitinib.]
[L04AC11, siltuximab, The metabolism of Tofacitinib can be decreased when combined with Siltuximab.]
[L01ED02, ceritinib, Tofacitinib may increase the bradycardic activities of Ceritinib.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Vorapaxar is combined with Tofacitinib.]
[L04AA33, vedolizumab, Vedolizumab may increase the immunosuppressive activities of Tofacitinib.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Tofacitinib.]
[L01XH04, belinostat, Belinostat may increase the immunosuppressive activities of Tofacitinib.]
[L01EM01, idelalisib, The metabolism of Tofacitinib can be decreased when combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, Peginterferon beta-1a may increase the immunosuppressive activities of Tofacitinib.]
[L01BC08, decitabine, Decitabine may increase the immunosuppressive activities of Tofacitinib.]
[L04AX05, pirfenidone, Pirfenidone may increase the immunosuppressive activities of Tofacitinib.]
[L01FX07, blinatumomab, Blinatumomab may increase the immunosuppressive activities of Tofacitinib.]
[L01XK01, olaparib, The metabolism of Tofacitinib can be decreased when combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Tofacitinib.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Tofacitinib.]
[N06AX11, mirtazapine, The metabolism of Tofacitinib can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, Secukinumab may increase the immunosuppressive activities of Tofacitinib.]
[L01EF01, palbociclib, The metabolism of Tofacitinib can be decreased when combined with Palbociclib.]
[L01XH03, panobinostat, Panobinostat may increase the immunosuppressive activities of Tofacitinib.]
[N02BE01, acetaminophen, The metabolism of Tofacitinib can be decreased when combined with Acetaminophen.]
[L01DC01, bleomycin, Bleomycin may increase the immunosuppressive activities of Tofacitinib.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Tofacitinib.]
[C01EB17, ivabradine, Tofacitinib may increase the bradycardic activities of Ivabradine.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Tofacitinib.]
[S01EC01, acetazolamide, The metabolism of Tofacitinib can be decreased when combined with Acetazolamide.]
[A02BC03, lansoprazole, The metabolism of Tofacitinib can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, Trabectedin may increase the immunosuppressive activities of Tofacitinib.]
[R03DX09, mepolizumab, Mepolizumab may increase the immunosuppressive activities of Tofacitinib.]
[J02AC05, isavuconazole, The metabolism of Tofacitinib can be decreased when combined with Isavuconazole.]
[J05AP10, elbasvir, The metabolism of Tofacitinib can be decreased when combined with Elbasvir.]
[L04AC13, ixekizumab, Ixekizumab may increase the immunosuppressive activities of Tofacitinib.]
[L01XX52, venetoclax, The metabolism of Tofacitinib can be decreased when combined with Venetoclax.]
[N04BC01, bromocriptine, The metabolism of Tofacitinib can be decreased when combined with Bromocriptine.]
[C08CA01, amlodipine, Amlodipine may increase the bradycardic activities of Tofacitinib.]
[C07AA19, bupranolol, Bupranolol may increase the bradycardic activities of Tofacitinib.]
[N07BC01, buprenorphine, The metabolism of Tofacitinib can be decreased when combined with Buprenorphine.]
[L01AB01, busulfan, Busulfan may increase the immunosuppressive activities of Tofacitinib.]
[L01XX27, arsenic trioxide, Arsenic trioxide may increase the immunosuppressive activities of Tofacitinib.]
[N06DA03, rivastigmine, Rivastigmine may increase the bradycardic activities of Tofacitinib.]
[M02AA03, clofezone, The metabolism of Tofacitinib can be decreased when combined with Rabeprazole.]
[S01GX07, azelastine, The metabolism of Tofacitinib can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Tofacitinib can be decreased when combined with Rucaparib.]
[L04AC12, brodalumab, Brodalumab may increase the immunosuppressive activities of Tofacitinib.]
[L01EF02, ribociclib, The metabolism of Tofacitinib can be decreased when combined with Ribociclib.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Tofacitinib.]
[N02BF02, pregabalin, Pregabalin may increase the bradycardic activities of Tofacitinib.]
[L04AC01, daclizumab, Daclizumab may increase the immunosuppressive activities of Tofacitinib.]
[J01XX08, linezolid, Linezolid may increase the immunosuppressive activities of Tofacitinib.]
[J05AE09, tipranavir, The metabolism of Tofacitinib can be decreased when combined with Tipranavir.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Tofacitinib.]
[L01EX10, midostaurin, The metabolism of Tofacitinib can be decreased when combined with Midostaurin.]
[L04AC14, sarilumab, The metabolism of Tofacitinib can be decreased when combined with Sarilumab.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Tofacitinib.]
[L04AC16, guselkumab, Guselkumab may increase the immunosuppressive activities of Tofacitinib.]
[D01AC10, bifonazole, The metabolism of Tofacitinib can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, Capecitabine may increase the immunosuppressive activities of Tofacitinib.]
[L01XX59, enasidenib, The metabolism of Tofacitinib can be decreased when combined with Enasidenib.]
[L01XH01, vorinostat, Vorinostat may increase the immunosuppressive activities of Tofacitinib.]
[C07AB07, bisoprolol, Bisoprolol may increase the bradycardic activities of Tofacitinib.]
[J05AG03, efavirenz, The metabolism of Tofacitinib can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, Bopindolol may increase the bradycardic activities of Tofacitinib.]
[L04AC02, basiliximab, Basiliximab may increase the immunosuppressive activities of Tofacitinib.]
[L01BA03, raltitrexed, Raltitrexed may increase the immunosuppressive activities of Tofacitinib.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Tofacitinib.]
[R03BA02, budesonide, Budesonide may increase the immunosuppressive activities of Tofacitinib.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Tofacitinib.]
[L01EL02, acalabrutinib, The metabolism of Tofacitinib can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Tofacitinib can be decreased when combined with Letermovir.]
[N01BX04, capsaicin, The metabolism of Tofacitinib can be decreased when combined with Capsaicin.]
[L02BB05, apalutamide, The metabolism of Tofacitinib can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, Carbamazepine may increase the immunosuppressive activities of Tofacitinib.]
[L03AB06, interferon alfa-n1, Interferon alfa-n1 may increase the immunosuppressive activities of Tofacitinib.]
[C07AG02, carvedilol, Carvedilol may increase the bradycardic activities of Tofacitinib.]
[B02BX09, fostamatinib, The metabolism of Tofacitinib can be decreased when combined with Fostamatinib.]
[L04AA37, baricitinib, Baricitinib may increase the immunosuppressive activities of Tofacitinib.]
[C07AB08, celiprolol, Celiprolol may increase the bradycardic activities of Tofacitinib.]
[L01XX62, ivosidenib, The metabolism of Tofacitinib can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Tofacitinib can be decreased when combined with Stiripentol.]
[L04AA39, emapalumab, Emapalumab may increase the immunosuppressive activities of Tofacitinib.]
[L01AD01, carmustine, Carmustine may increase the immunosuppressive activities of Tofacitinib.]
[L04AA43, ravulizumab, Ravulizumab may increase the immunosuppressive activities of Tofacitinib.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Tofacitinib.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Tofacitinib.]
[P02BX04, triclabendazole, The metabolism of Tofacitinib can be decreased when combined with Triclabendazole.]
[L04AA42, siponimod, Siponimod may increase the immunosuppressive activities of Tofacitinib.]
[J01FA09, clarithromycin, The metabolism of Tofacitinib can be decreased when combined with Clarithromycin.]
[H02AB14, cloprednol, Cloprednol may increase the immunosuppressive activities of Tofacitinib.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Tofacitinib.]
[H02AB17, cortivazol, Cortivazol may increase the immunosuppressive activities of Tofacitinib.]
[L04AC18, risankizumab, Risankizumab may increase the immunosuppressive activities of Tofacitinib.]
[L01EM03, alpelisib, The metabolism of Tofacitinib can be decreased when combined with Alpelisib.]
[L04AA44, upadacitinib, Upadacitinib may increase the immunosuppressive activities of Tofacitinib.]
[N07XX11, pitolisant, The serum concentration of Tofacitinib can be decreased when it is combined with Pitolisant.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Tofacitinib.]
[H02AB13, deflazacort, Deflazacort may increase the immunosuppressive activities of Tofacitinib.]
[L01FD01, trastuzumab, Trastuzumab may increase the immunosuppressive activities of Tofacitinib.]
[L01FD03, ado-trastuzumab emtansine, Trastuzumab emtansine may increase the immunosuppressive activities of Tofacitinib.]
[N02CC08, lasmiditan, Lasmiditan may increase the bradycardic activities of Tofacitinib.]
[L04AX09, diroximel fumarate, Diroximel fumarate may increase the immunosuppressive activities of Tofacitinib.]
[N03AX25, cenobamate, The metabolism of Tofacitinib can be decreased when combined with Cenobamate.]
[L04AA53, teprotumumab, Teprotumumab may increase the immunosuppressive activities of Tofacitinib.]
[J05AB16, remdesivir, The metabolism of Tofacitinib can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The metabolism of Tofacitinib can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Tofacitinib can be decreased when combined with Amprenavir.]
[L04AA38, ozanimod, Ozanimod may increase the immunosuppressive activities of Tofacitinib.]
[L01XF03, bexarotene, Bexarotene may increase the immunosuppressive activities of Tofacitinib.]
[C08CA16, clevidipine, The metabolism of Tofacitinib can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Tofacitinib can be decreased when combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Tofacitinib can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, Chlorambucil may increase the immunosuppressive activities of Tofacitinib.]
[S03AA08, chloramphenicol, The metabolism of Tofacitinib can be decreased when combined with Chloramphenicol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Tofacitinib.]
[D07XB03, fluprednidene, Fluprednidene may increase the immunosuppressive activities of Tofacitinib.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Tofacitinib.]
[L04AA47, inebilizumab, Inebilizumab may increase the immunosuppressive activities of Tofacitinib.]
[R05CB11, stepronin, Stepronin may increase the immunosuppressive activities of Tofacitinib.]
[L04AC19, satralizumab, The serum concentration of Tofacitinib can be decreased when it is combined with Satralizumab.]
[L01EX23, pralsetinib, The metabolism of Tofacitinib can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Tofacitinib.]
[N06BX18, vinpocetine, Tofacitinib may increase the bradycardic activities of Vinpocetine.]
[B06AC06, berotralstat, The metabolism of Tofacitinib can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Tofacitinib can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, Fludarabine may increase the immunosuppressive activities of Tofacitinib.]
[L04AD03, voclosporin, Voclosporin may increase the immunosuppressive activities of Tofacitinib.]
[P03AX07, abametapir, The serum concentration of Tofacitinib can be increased when it is combined with Abametapir.]
[R03BA03, flunisolide, Flunisolide may increase the immunosuppressive activities of Tofacitinib.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may increase the immunosuppressive activities of Tofacitinib.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Tofacitinib.]
[L03AB10, peginterferon alfa-2b, Peginterferon alfa-2b may increase the immunosuppressive activities of Tofacitinib.]
[A02BA01, cimetidine, The metabolism of Tofacitinib can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, Cinnarizine may increase the bradycardic activities of Tofacitinib.]
[L01XX73, sotorasib, The serum concentration of Tofacitinib can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Tofacitinib can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Cisplatin may increase the immunosuppressive activities of Tofacitinib.]
[N06AB04, citalopram, The metabolism of Tofacitinib can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, Pegcetacoplan may increase the immunosuppressive activities of Tofacitinib.]
[L04AA48, belumosudil, Belumosudil may increase the immunosuppressive activities of Tofacitinib.]
[P01CA03, fexinidazole, The metabolism of Tofacitinib can be decreased when combined with Fexinidazole.]
[L04AA51, anifrolumab, Anifrolumab may increase the immunosuppressive activities of Tofacitinib.]
[N06AX25, St. John's wort extract, The metabolism of Tofacitinib can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, Ropeginterferon alfa-2b may increase the immunosuppressive activities of Tofacitinib.]
[J04BA01, clofazimine, The metabolism of Tofacitinib can be decreased when combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Tofacitinib.]
[S01EA04, clonidine, Clonidine may increase the bradycardic activities of Tofacitinib.]
[C01EB24, mavacamten, The serum concentration of Tofacitinib can be decreased when it is combined with Mavacamten.]
[L04AC22, spesolimab, Spesolimab may increase the immunosuppressive activities of Tofacitinib.]
[L04AA56, deucravacitinib, Deucravacitinib may increase the immunosuppressive activities of Tofacitinib.]
[N05AH02, clozapine, The metabolism of Tofacitinib can be decreased when combined with Clozapine.]
[H01AC08, somatrogon, The metabolism of Tofacitinib can be increased when combined with Somatrogon.]
[L04AC21, bimekizumab, Bimekizumab may increase the immunosuppressive activities of Tofacitinib.]
[M04AC01, colchicine, The metabolism of Tofacitinib can be decreased when combined with Colchicine.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Tofacitinib is combined with Leflunomide.]
[L01BB07, nelarabine, Nelarabine may increase the immunosuppressive activities of Tofacitinib.]
[J01FA15, telithromycin, The metabolism of Tofacitinib can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, Ciclesonide may increase the immunosuppressive activities of Tofacitinib.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Tofacitinib.]
[J02AC02, itraconazole, The metabolism of Tofacitinib can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Tofacitinib.]
[N05BA10, ketazolam, The metabolism of Tofacitinib can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The metabolism of Tofacitinib can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Tofacitinib can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Tofacitinib may increase the bradycardic activities of Lacidipine.]
[N03AX09, lamotrigine, Lamotrigine may increase the bradycardic activities of Tofacitinib.]
[C08CA11, manidipine, The metabolism of Tofacitinib can be decreased when combined with Manidipine.]
[C07AA14, mepindolol, Tofacitinib may increase the bradycardic activities of Mepindolol.]
[H02AB15, meprednisone, Meprednisone may increase the immunosuppressive activities of Tofacitinib.]
[R06AD07, mequitazine, The metabolism of Tofacitinib can be decreased when combined with Mequitazine.]
[C04AX01, cyclandelate, Cyclandelate may increase the bradycardic activities of Tofacitinib.]
[L04AA15, alefacept, Alefacept may increase the immunosuppressive activities of Tofacitinib.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Tofacitinib.]
[J01FA03, midecamycin, The metabolism of Tofacitinib can be decreased when combined with Midecamycin.]
[L01AA01, cyclophosphamide, Cyclophosphamide may increase the immunosuppressive activities of Tofacitinib.]
[S01XA18, cyclosporine, Tofacitinib may increase the immunosuppressive activities of Cyclosporine.]
[C03XA02, conivaptan, The metabolism of Tofacitinib can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, Cytarabine may increase the immunosuppressive activities of Tofacitinib.]
[M01AH05, etoricoxib, The metabolism of Tofacitinib can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, Dacarbazine may increase the immunosuppressive activities of Tofacitinib.]
[L01DA01, dactinomycin, Dactinomycin may increase the immunosuppressive activities of Tofacitinib.]
[G03XA01, danazol, The metabolism of Tofacitinib can be decreased when combined with Danazol.]
[L01DB02, daunorubicin, The metabolism of Tofacitinib can be decreased when combined with Daunorubicin.]
[C07AB12, nebivolol, Nebivolol may increase the bradycardic activities of Tofacitinib.]
[N06AX06, nefazodone, The metabolism of Tofacitinib can be decreased when combined with Nefazodone.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Tofacitinib.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tofacitinib.]
[N06AA01, desipramine, The metabolism of Tofacitinib can be decreased when combined with Desipramine.]
[D07XC02, desoximetasone, Desoximetasone may increase the immunosuppressive activities of Tofacitinib.]
[L01XA03, oxaliplatin, Oxaliplatin may increase the immunosuppressive activities of Tofacitinib.]
[N03AF02, oxcarbazepine, The metabolism of Tofacitinib can be decreased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Tofacitinib can be decreased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Tofacitinib can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Tofacitinib.]
[N06AB05, paroxetine, The metabolism of Tofacitinib can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Tofacitinib.]
[A03AX15, peppermint oil, The metabolism of Tofacitinib can be decreased when combined with Peppermint oil.]
[N05BA01, diazepam, The metabolism of Tofacitinib can be decreased when combined with Diazepam.]
[A03AX04, pinaverium, Tofacitinib may increase the bradycardic activities of Pinaverium.]
[L01DC04, ixabepilone, Ixabepilone may increase the immunosuppressive activities of Tofacitinib.]
[L01EB02, erlotinib, The metabolism of Tofacitinib can be decreased when combined with Erlotinib.]
[L01DB08, pirarubicin, Pirarubicin may increase the immunosuppressive activities of Tofacitinib.]
[L02AA01, diethylstilbestrol, The metabolism of Tofacitinib can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Tofacitinib can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, Difluocortolone may increase the immunosuppressive activities of Tofacitinib.]
[C01AA05, digoxin, Digoxin may increase the bradycardic activities of Tofacitinib.]
[L01XX24, pegaspargase, Pegaspargase may increase the immunosuppressive activities of Tofacitinib.]
[N02CA01, dihydroergotamine, The metabolism of Tofacitinib can be decreased when combined with Dihydroergotamine.]
[L04AX04, lenalidomide, Lenalidomide may increase the immunosuppressive activities of Tofacitinib.]
[J05AE08, atazanavir, The metabolism of Tofacitinib can be decreased when combined with Atazanavir.]
[C08DB01, diltiazem, The metabolism of Tofacitinib can be decreased when combined with Diltiazem.]
[M02AX03, dimethyl sulfoxide, The metabolism of Tofacitinib can be decreased when combined with Dimethyl sulfoxide.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Tofacitinib.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tofacitinib.]
[S01XA23, sirolimus, Sirolimus may increase the immunosuppressive activities of Tofacitinib.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Tofacitinib is combined with Natalizumab.]
[S02AA12, rifamycin SV, The metabolism of Tofacitinib can be decreased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Tofacitinib can be increased when combined with Rifapentine.]
[L04AA21, efalizumab, Efalizumab may increase the immunosuppressive activities of Tofacitinib.]
[L01EX01, sunitinib, The metabolism of Tofacitinib can be decreased when combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Tofacitinib can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, Bortezomib may increase the immunosuppressive activities of Tofacitinib.]
[C01EB18, ranolazine, The metabolism of Tofacitinib can be decreased when combined with Ranolazine.]
[L01DB01, doxorubicin, The metabolism of Tofacitinib can be decreased when combined with Doxorubicin.]
[C07AB13, talinolol, Tofacitinib may increase the bradycardic activities of Talinolol.]
[H01AA01, corticotropin, Corticotropin may increase the immunosuppressive activities of Tofacitinib.]
[L01AX03, temozolomide, Temozolomide may increase the immunosuppressive activities of Tofacitinib.]
[G04BD05, terodiline, Tofacitinib may increase the bradycardic activities of Terodiline.]
[C07AA16, tertatolol, Tofacitinib may increase the bradycardic activities of Tertatolol.]
[G01AF08, tioconazole, The metabolism of Tofacitinib can be decreased when combined with Tioconazole.]
[N05BA23, tofisopam, The metabolism of Tofacitinib can be decreased when combined with Tofisopam.]
[M01AG02, tolfenamic acid, Tofacitinib may increase the bradycardic activities of Tolfenamic acid.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Tofacitinib.]
[H02CA01, trilostane, Trilostane may increase the immunosuppressive activities of Tofacitinib.]
[L01AA07, trofosfamide, Trofosfamide may increase the immunosuppressive activities of Tofacitinib.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Tofacitinib.]
[L01CA04, vinorelbine, Vinorelbine may increase the immunosuppressive activities of Tofacitinib.]
[C08CA12, mepirodipine, The metabolism of Tofacitinib can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Tofacitinib can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, Epirubicin may increase the immunosuppressive activities of Tofacitinib.]
[N03AX15, zonisamide, Zonisamide may increase the bradycardic activities of Tofacitinib.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Tofacitinib.]
[L01XA02, carboplatin, Carboplatin may increase the immunosuppressive activities of Tofacitinib.]
[C02AC02, guanfacine, Guanfacine may increase the bradycardic activities of Tofacitinib.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Tofacitinib.]
[N02CA02, ergotamine, The metabolism of Tofacitinib can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Tofacitinib can be decreased when combined with Erythromycin.]
[L01XX11, estramustine, Estramustine may increase the immunosuppressive activities of Tofacitinib.]
[R03BA09, fluticasone furoate, The metabolism of Tofacitinib can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Tofacitinib can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Tofacitinib can be decreased when combined with Fluvastatin.]
[N03AD01, ethosuximide, Ethosuximide may increase the bradycardic activities of Tofacitinib.]
[L01CB01, etoposide, The metabolism of Tofacitinib can be decreased when combined with Etoposide.]
[L04AD02, tacrolimus, The metabolism of Tofacitinib can be decreased when combined with Tacrolimus.]
[R06AX11, astemizole, The metabolism of Tofacitinib can be decreased when combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Tofacitinib can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Tofacitinib can be decreased when combined with Fluvoxamine.]
[L04AA02, muromonab-CD3, Muromonab may increase the immunosuppressive activities of Tofacitinib.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Tofacitinib.]
[V03AF02, dexrazoxane, Dexrazoxane may increase the immunosuppressive activities of Tofacitinib.]
[C08CA02, felodipine, Felodipine may increase the bradycardic activities of Tofacitinib.]
[C08EA01, fendiline, Tofacitinib may increase the bradycardic activities of Fendiline.]
[N02AB03, fentanyl, Fentanyl may increase the bradycardic activities of Tofacitinib.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Tofacitinib.]
[L01BB06, clofarabine, Clofarabine may increase the immunosuppressive activities of Tofacitinib.]
[L04AA40, cladribine, Cladribine may increase the immunosuppressive activities of Tofacitinib.]
[J02AC01, fluconazole, The metabolism of Tofacitinib can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Flucytosine may increase the immunosuppressive activities of Tofacitinib.]
[H02AA02, fludrocortisone, Fludrocortisone may increase the immunosuppressive activities of Tofacitinib.]
[D07XB01, flumethasone, Flumethasone may increase the immunosuppressive activities of Tofacitinib.]
[N07CA03, flunarizine, Flunarizine may increase the bradycardic activities of Tofacitinib.]
[D07AC08, fluocinonide, Fluocinonide may increase the immunosuppressive activities of Tofacitinib.]
[H02AB03, fluocortolone, Fluocortolone may increase the immunosuppressive activities of Tofacitinib.]
[V03AZ01, ethanol, The metabolism of Tofacitinib can be decreased when combined with Ethanol.]
[L01BC09, floxuridine, Floxuridine may increase the immunosuppressive activities of Tofacitinib.]
[S01CB05, fluorometholone, Fluorometholone may increase the immunosuppressive activities of Tofacitinib.]
[L01BC02, fluorouracil, Fluorouracil may increase the immunosuppressive activities of Tofacitinib.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Tofacitinib.]
[N05AG01, fluspirilene, Fluspirilene may increase the bradycardic activities of Tofacitinib.]
[J05AE10, darunavir, The metabolism of Tofacitinib can be decreased when combined with Darunavir.]
[N06DA04, galantamine, Galantamine may increase the bradycardic activities of Tofacitinib.]
[C08DA02, gallopamil, Tofacitinib may increase the bradycardic activities of Gallopamil.]
[L01EA02, dasatinib, The metabolism of Tofacitinib can be decreased when combined with Dasatinib.]
[N04BC06, cabergoline, The metabolism of Tofacitinib can be decreased when combined with Cabergoline.]
[N03AD03, methsuximide, Methsuximide may increase the bradycardic activities of Tofacitinib.]
[N01AH02, alfentanil, Alfentanil may increase the bradycardic activities of Tofacitinib.]
[L01EH01, lapatinib, The metabolism of Tofacitinib can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Tofacitinib can be decreased when combined with Glyburide.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the bradycardic activities of Tofacitinib.]
[L01EX02, sorafenib, The metabolism of Tofacitinib can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, Esmolol may increase the bradycardic activities of Tofacitinib.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Tofacitinib.]
[N05AD01, haloperidol, The metabolism of Tofacitinib can be decreased when combined with Haloperidol.]
[L01CE02, irinotecan, Irinotecan may increase the immunosuppressive activities of Tofacitinib.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Tofacitinib.]
[C09CA01, losartan, The metabolism of Tofacitinib can be decreased when combined with Losartan.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Tofacitinib.]
[L01XX03, altretamine, Altretamine may increase the immunosuppressive activities of Tofacitinib.]
[C08CA10, nilvadipine, The metabolism of Tofacitinib can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may increase the bradycardic activities of Tofacitinib.]
[C02DB02, hydralazine, The metabolism of Tofacitinib can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Tofacitinib.]
[S02BA01, hydrocortisone, Hydrocortisone may increase the immunosuppressive activities of Tofacitinib.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Tofacitinib.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Tofacitinib.]
[L01XX05, hydroxyurea, Hydroxyurea may increase the immunosuppressive activities of Tofacitinib.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Tofacitinib.]
[L01DB06, idarubicin, Idarubicin may increase the immunosuppressive activities of Tofacitinib.]
[L01AA06, ifosfamide, The metabolism of Tofacitinib can be decreased when combined with Ifosfamide.]
[N01AH03, sufentanil, Sufentanil may increase the bradycardic activities of Tofacitinib.]
[L01CD01, paclitaxel, Paclitaxel may increase the immunosuppressive activities of Tofacitinib.]
[R01AD07, tixocortol, Tixocortol may increase the immunosuppressive activities of Tofacitinib.]
[M03BX02, tizanidine, Tizanidine may increase the bradycardic activities of Tofacitinib.]
[L01CE01, topotecan, The metabolism of Tofacitinib can be decreased when combined with Topotecan.]
[S01BC01, indomethacin, Indomethacin may increase the immunosuppressive activities of Tofacitinib.]
[L03AB04, interferon alfa-2a, Interferon alfa-2a may increase the immunosuppressive activities of Tofacitinib.]
[L03AB05, interferon alfa-2b, Interferon alfa-2b may increase the immunosuppressive activities of Tofacitinib.]
[N06AX17, milnacipran, The metabolism of Tofacitinib can be decreased when combined with Milnacipran.]
[L04AA25, eculizumab, Eculizumab may increase the immunosuppressive activities of Tofacitinib.]
[C10AA06, cerivastatin, The metabolism of Tofacitinib can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Tofacitinib.]
[C07AA01, alprenolol, Alprenolol may increase the bradycardic activities of Tofacitinib.]
[L03AB09, interferon alfacon-1, Interferon alfacon-1 may increase the immunosuppressive activities of Tofacitinib.]
[J04AC01, isoniazid, The metabolism of Tofacitinib can be decreased when combined with Isoniazid.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Tofacitinib.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Tocilizumab is combined with Tofacitinib.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Tofacitinib.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Tofacitinib.]
[J02AB02, ketoconazole, The metabolism of Tofacitinib can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Tofacitinib can be decreased when combined with Levoketoconazole.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Abatacept is combined with Tofacitinib.]
[C07AG01, labetalol, Labetalol may increase the bradycardic activities of Tofacitinib.]
[N03AX18, lacosamide, Lacosamide may increase the bradycardic activities of Tofacitinib.]
[L01DC03, mitomycin, Mitomycin may increase the immunosuppressive activities of Tofacitinib.]
[C08EX01, lidoflazine, Tofacitinib may increase the bradycardic activities of Lidoflazine.]
[L01AD02, lomustine, Lomustine may increase the immunosuppressive activities of Tofacitinib.]
[A07DA03, loperamide, Loperamide may increase the bradycardic activities of Tofacitinib.]
[C10AA02, lovastatin, The metabolism of Tofacitinib can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, Temsirolimus may increase the immunosuppressive activities of Tofacitinib.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the bradycardic activities of Tofacitinib.]
[L01BA05, pralatrexate, Pralatrexate may increase the immunosuppressive activities of Tofacitinib.]
[L01EA03, nilotinib, The metabolism of Tofacitinib can be decreased when combined with Nilotinib.]
[L01AA05, mechlorethamine, Mechlorethamine may increase the immunosuppressive activities of Tofacitinib.]
[P01BC02, mefloquine, The metabolism of Tofacitinib can be decreased when combined with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Tofacitinib.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Tofacitinib.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Tofacitinib.]
[L01AA03, melphalan, Melphalan may increase the immunosuppressive activities of Tofacitinib.]
[H01CB03, lanreotide, The metabolism of Tofacitinib can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Tofacitinib can be decreased when combined with Methadone.]
[H03BB02, methimazole, The metabolism of Tofacitinib can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Pemetrexed may increase the immunosuppressive activities of Tofacitinib.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Tofacitinib.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Tofacitinib.]
[C02AB01, methyldopa, Methyldopa may increase the bradycardic activities of Tofacitinib.]
[V04CG05, methylene blue, The metabolism of Tofacitinib can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Tofacitinib can be decreased when combined with Methylergometrine.]
[H02AB04, methylprednisolone, Methylprednisolone may increase the immunosuppressive activities of Tofacitinib.]
[C07AB02, metoprolol, Metoprolol may increase the bradycardic activities of Tofacitinib.]
[P01AB01, metronidazole, The metabolism of Tofacitinib can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Tofacitinib can be decreased when combined with Metyrapone.]
[S02AA13, miconazole, The metabolism of Tofacitinib can be decreased when combined with Miconazole.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Tofacitinib.]
[N05CD08, midazolam, The metabolism of Tofacitinib can be decreased when combined with Midazolam.]
[C01CA17, midodrine, Midodrine may increase the bradycardic activities of Tofacitinib.]
[G03XB01, mifepristone, The metabolism of Tofacitinib can be decreased when combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Tofacitinib.]
[L01XX23, mitotane, The metabolism of Tofacitinib can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, Mitoxantrone may increase the immunosuppressive activities of Tofacitinib.]
[L03AC01, aldesleukin, The metabolism of Tofacitinib can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Tofacitinib can be decreased when combined with Amiodarone.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Tofacitinib.]
[L04AA52, ofatumumab, Ofatumumab may increase the immunosuppressive activities of Tofacitinib.]
[L01EX03, pazopanib, The metabolism of Tofacitinib can be decreased when combined with Pazopanib.]
[L04AA06, mycophenolic acid, Mycophenolic acid may increase the immunosuppressive activities of Tofacitinib.]
[G03XC01, raloxifene, The metabolism of Tofacitinib can be decreased when combined with Raloxifene.]
[N03AB05, fosphenytoin, The metabolism of Tofacitinib can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, Interferon beta-1b may increase the immunosuppressive activities of Tofacitinib.]
[C07AA12, nadolol, Nadolol may increase the bradycardic activities of Tofacitinib.]
[V03AB15, naloxone, The metabolism of Tofacitinib can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Tofacitinib.]
[L01CD02, docetaxel, The metabolism of Tofacitinib can be decreased when combined with Docetaxel.]
[N01AH06, remifentanil, Remifentanil may increase the bradycardic activities of Tofacitinib.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Tofacitinib.]
[N06AX23, desvenlafaxine, The metabolism of Tofacitinib can be decreased when combined with Desvenlafaxine.]
[L01XX01, amsacrine, Amsacrine may increase the immunosuppressive activities of Tofacitinib.]
[C08CA04, nicardipine, The metabolism of Tofacitinib can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, Nifedipine may increase the bradycardic activities of Tofacitinib.]
[C08CA06, nimodipine, Nimodipine may increase the bradycardic activities of Tofacitinib.]
[C08CA07, nisoldipine, Nisoldipine may increase the bradycardic activities of Tofacitinib.]
[C08CA08, nitrendipine, Nitrendipine may increase the bradycardic activities of Tofacitinib.]
[R07AX01, nitric oxide, The metabolism of Tofacitinib can be decreased when combined with Nitric Oxide.]
[S01AE02, norfloxacin, The metabolism of Tofacitinib can be decreased when combined with Norfloxacin.]
[R05DA07, noscapine, The metabolism of Tofacitinib can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Tofacitinib.]
[G02CA02, nylidrin, Nylidrin may increase the bradycardic activities of Tofacitinib.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Tofacitinib.]
[H01CB02, octreotide, The metabolism of Tofacitinib can be decreased when combined with Octreotide.]
[J01FA05, oleandomycin, The metabolism of Tofacitinib can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, Rilonacept may increase the immunosuppressive activities of Tofacitinib.]
[A02BC01, omeprazole, The metabolism of Tofacitinib can be decreased when combined with Omeprazole.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Tofacitinib.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Tofacitinib.]
[C07AA02, oxprenolol, Oxprenolol may increase the bradycardic activities of Tofacitinib.]
[A14AA05, oxymetholone, The metabolism of Tofacitinib can be decreased when combined with Oxymetholone.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Tofacitinib.]
[H02AB05, paramethasone, The metabolism of Tofacitinib can be decreased when combined with Paramethasone.]
[C07AA23, penbutolol, Penbutolol may increase the bradycardic activities of Tofacitinib.]
[N05AG03, penfluridol, Tofacitinib may increase the bradycardic activities of Penfluridol.]
[M01CC01, penicillamine, Penicillamine may increase the immunosuppressive activities of Tofacitinib.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tofacitinib.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tofacitinib.]
[N05CA01, pentobarbital, The metabolism of Tofacitinib can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Pentostatin may increase the immunosuppressive activities of Tofacitinib.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Tofacitinib.]
[C08EX02, perhexiline, Perhexiline may increase the bradycardic activities of Tofacitinib.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Tofacitinib.]
[N06AF03, phenelzine, The metabolism of Tofacitinib can be decreased when combined with Phenelzine.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Tofacitinib.]
[N03AA02, phenobarbital, The metabolism of Tofacitinib can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Tofacitinib.]
[N03AB02, phenytoin, The metabolism of Tofacitinib can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Golimumab is combined with Tofacitinib.]
[L02BB03, bicalutamide, The metabolism of Tofacitinib can be decreased when combined with Bicalutamide.]
[C08CX01, mibefradil, The metabolism of Tofacitinib can be decreased when combined with Mibefradil.]
[S01EB01, pilocarpine, The metabolism of Tofacitinib can be decreased when combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Tofacitinib can be decreased when combined with Pimozide.]
[C07AA03, pindolol, Pindolol may increase the bradycardic activities of Tofacitinib.]
[J05AE01, saquinavir, The metabolism of Tofacitinib can be decreased when combined with Saquinavir.]
[J05AG02, delavirdine, The metabolism of Tofacitinib can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Tofacitinib can be decreased when combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Tofacitinib.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Tofacitinib.]
[L04AC08, canakinumab, Canakinumab may increase the immunosuppressive activities of Tofacitinib.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Tofacitinib.]
[J05AE03, ritonavir, The metabolism of Tofacitinib can be decreased when combined with Ritonavir.]
[C07AB01, practolol, Practolol may increase the bradycardic activities of Tofacitinib.]
[S03BA02, prednisolone, Prednisolone may increase the immunosuppressive activities of Tofacitinib.]
[H02AB07, prednisone, Prednisone may increase the immunosuppressive activities of Tofacitinib.]
[C01DX02, prenylamine, Prenylamine may increase the bradycardic activities of Tofacitinib.]
[P01BA03, primaquine, The metabolism of Tofacitinib can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Tofacitinib can be increased when combined with Primidone.]
[L01XB01, procarbazine, Procarbazine may increase the immunosuppressive activities of Tofacitinib.]
[C01BC03, propafenone, Propafenone may increase the bradycardic activities of Tofacitinib.]
[N01AX10, propofol, The metabolism of Tofacitinib can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Tofacitinib can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, Propranolol may increase the bradycardic activities of Tofacitinib.]
[H03BA02, propylthiouracil, Propylthiouracil may increase the immunosuppressive activities of Tofacitinib.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Tofacitinib.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Tofacitinib.]
[C01BA01, quinidine, The metabolism of Tofacitinib can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Tofacitinib can be decreased when combined with Quinine.]
[J04AB02, rifampin, The metabolism of Tofacitinib can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Tofacitinib can be decreased when combined with Roxithromycin.]
[C05CA01, rutin, The metabolism of Tofacitinib can be decreased when combined with Rutin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tofacitinib.]
[L01FA03, obinutuzumab, Obinutuzumab may increase the immunosuppressive activities of Tofacitinib.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Tofacitinib.]
[H01CB01, somatostatin, The metabolism of Tofacitinib can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, Sotalol may increase the bradycardic activities of Tofacitinib.]
[L01CD04, cabazitaxel, Cabazitaxel may increase the immunosuppressive activities of Tofacitinib.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tofacitinib.]
[N03AG01, valproic acid, The metabolism of Tofacitinib can be decreased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, Hydrocortisone butyrate may increase the immunosuppressive activities of Tofacitinib.]
